论文部分内容阅读
乳腺癌是较早开始个体化治疗的肿瘤之一。表皮细胞生长因子受体(epidermal growth factor receptor,EGFR)的表达与乳腺癌组织学分期、生长速度呈正相关,可作为乳腺癌患者预后的指标之一。临床上,长春瑞滨(Vinorelbine,NVB)主要作为耐药性晚期乳腺癌的挽救性化疗药物,单药治疗亦具有一定疗效。该研究结果发现,乳腺癌组织EGFR表达与NVB的敏感性相关(P=0.001),而与紫杉醇、阿霉素及5-氟尿嘧啶无相关性。EGFR阴性乳腺癌细胞MDA-MB-435s对NVB耐药,而EGFR阳性细胞MCF-7则敏感,但是EGFR中和性抗体会降低敏感性。进一步研究发现,NVB会引起MCF-7表面EGFR表达上调,以及胞内ERK1/2激酶的磷酸化,且这一效应会被抗EGFR抗体部分抑制。研究结果表明,乳腺癌细胞对NVB的敏感性与膜表面EGFR表达水平相关,提示EGFR可作为NVB治疗敏感性的预测分子。
Breast cancer is one of the tumors that began treatment as early as individualized. The expression of epidermal growth factor receptor (EGFR) is positively correlated with histological staging and growth rate of breast cancer, which may be used as one of the prognostic indicators in patients with breast cancer. Clinically, Vinorelbine (NVB) is mainly used as a salvage chemotherapy drug for resistant advanced breast cancer. Monotherapy also has a certain effect. The study found that breast cancer EGFR expression and NVB sensitivity (P = 0.001), but not with paclitaxel, doxorubicin and 5-fluorouracil no correlation. EGFR-negative breast cancer cells MDA-MB-435s are resistant to NVB, while EGFR-positive cells MCF-7 are sensitive, but neutralizing antibodies EGFR will reduce the sensitivity. Further study found that NVB caused the up-regulation of EGFR expression on MCF-7 surface and phosphorylation of intracellular ERK1 / 2 kinase, and this effect was partially inhibited by anti-EGFR antibody. The results show that the sensitivity of breast cancer cells to NVB and membrane surface EGFR expression level, suggesting that EGFR can be used as a predictive value of NVB treatment sensitivity.